Biological
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
Clinical Trials of Quadrivalent Influenza Vaccine
NCT06824519
completed
Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years
NCT06095947
completedphase_3
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
NCT05431725
Clinical Trials (3)
Showing 3 of 3 trials
NCT06824519Phase 1
Clinical Trials of Quadrivalent Influenza Vaccine
NCT06095947
Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years
NCT05431725Phase 3
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3